Pharmacokinetics and Pharmacodynamics of High Dose Ceftriaxone in Patients With Sepsis
Key facts
- Who runs it
- Prince of Songkla University
- Where
- Thailand1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 20 people enrolled
- Started
- 1 Jun 2024
- Ended
- 28 Feb 2025
- Type of study
- Observational
- Record updated
- 24 November 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Participants aging over 18 years old with the symptoms of systemic inflammatory response syndrome (SIRS) which requires at least two of the following symptoms
- Temperature over 38 degree Celsius (Fever) or lower than 36 degree Celsius (hypothermia)
- Tachycardia
- Tachypnea, or the detection of PaCO2 under 32 mmHg, or hypocapnia due to hyperventilation
- Participants are about to received Ceftriaxone by the physician
- Weighting equal to or more than 50 kg
Who cannot take part
- Patients received Ceftriaxone within 3 days before the participation
- Having CLcr lower than 50 ml/min, or receiving hemodialysis, or renal replacement therapy
- Patients with the clinical record of the severe allergy to β-lactam or Ceftriaxone
- Decompensated liver disease
- Having the level of serum albumin lower than 2.5 g/dl
- Having a culture result of being resistant to Ceftriaxone
- Meningitis patients
- Pregnant and lactating
- Septic shock patients
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
As the general treatment method for infectious diseases is to prescribe antibiotics which can be complete at the empirical treatment with the control of the sources of infection, the types of antibiotics that contain the broad spectrum and the proper dose to reduce the severity of infection play an important role. Especially, patients with sepsis should receive antibiotics within 1 hours after the diagnosis since the delay of 1 hour will decrease the rate of survival by 7.6 percent. Ceftriaxone is considered to be Cephalosporin, the antibiotics in the group of β-lactams antibiotic which kills bacteria by preventing the creation of significant cell walls. Ceftriaxone is soluble and can be excreted by the kidney. It is a β-lactams broad spectrum which can kill bacteria broadly including various types of gram-positive and gram-negative. The effectiveness of Ceftriaxone is in accord with the percentage of time that the level of the drug is beyond the minimum inhibitory concentration. According to the research in animals conducted by Craig WA and others, the drug effect to prevent the bacteria growth will occur when the %ft>MIC is more than at least 40%. The rate of prevention will reach the maximal bactericidal effect when the %ft>MIC is equal to 60 to 70%. At the moment, physicians prefer the 60 to 70% of %ft>MIC in the group of Cephalosporins drugs as the main pharmacodynamics to cope with infections.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 24 November 2025